GHK CU is a recurring topic in our peptide coverage. This hub collects every article tagged GHK CU, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-graded ranking of the topical matrikine and copper peptides marketed for collagen, elastin and firmness — GHK-Cu, Matrixyl, palmitoyl tripeptide-1 and Synthe'6 — separating small human RCTs from in-vitro mechanism and marketing.
An evidence-graded ranking of the peptides marketed for cellulite — oral collagen peptides, GHK-Cu, AOD-9604 and HGH Fragment 176-191 — separating the one modest human signal from mechanism, marketing and WADA-banned research chemicals.
An evidence-graded review of the peptides marketed for cartilage and meniscus repair. The honest 2026 verdict: no peptide has a placebo-controlled human trial showing cartilage regrowth or meniscus repair, and the only controlled human data belongs to pentosan polysulfate — which is not even a peptide.
LL-37, GHK-Cu, thymosin β4/TB-500 and BPC-157 all have real wound-healing biology — but not a single controlled human burn trial. A clinical-editorial ranking of what the evidence actually supports in 2026.
A clinical, evidence-ranked look at the peptides marketed for back injury, spinal soft-tissue repair, and disc health — what the published data actually supports, and what is marketing.
An evidence-first ranking of the peptides most studied for aging and healthspan — elamipretide, GHK-Cu, thymalin, epitalon and MOTS-c — separating real human data from rodent and in-vitro hype.
An evidence-graded ranking of the peptides studied for atrophic acne scarring — copper tripeptide, the TriHex matrikine blend, and Matrixyl — separating the small human adjunct data from in-vitro mechanism and marketing.
A clinical monograph on GHK-Cu (copper tripeptide-1) — the endogenous copper-binding peptide with genuine topical human data for skin and wound healing, and a speculative injectable story with no controlled human evidence.
Copper Tripeptide-1 is the cosmetic INCI name for GHK-Cu. This monograph covers its regulatory identity, the CIR safety review, topical skin-penetration science, formulation rules, and the cosmetic-vs-drug line that governs how it can legally be sold.
GHK CU is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged GHK CU, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.